Tarsus Pharmaceuticals Statistics
Total Valuation
TARS has a market cap or net worth of $3.02 billion. The enterprise value is $2.69 billion.
Important Dates
The last earnings date was Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TARS has 42.21 million shares outstanding. The number of shares has increased by 12.73% in one year.
| Current Share Class | 42.21M |
| Shares Outstanding | 42.21M |
| Shares Change (YoY) | +12.73% |
| Shares Change (QoQ) | +0.58% |
| Owned by Insiders (%) | 7.86% |
| Owned by Institutions (%) | 94.87% |
| Float | 30.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 117.08 |
| PS Ratio | 7.97 |
| Forward PS | 5.25 |
| PB Ratio | 9.06 |
| P/TBV Ratio | 9.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.29, with a Debt / Equity ratio of 0.22.
| Current Ratio | 4.29 |
| Quick Ratio | 4.07 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.68 |
Financial Efficiency
Return on equity (ROE) is -28.35% and return on invested capital (ROIC) is -15.21%.
| Return on Equity (ROE) | -28.35% |
| Return on Assets (ROA) | -12.00% |
| Return on Invested Capital (ROIC) | -15.21% |
| Return on Capital Employed (ROCE) | -20.94% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | -$251,263 |
| Employee Count | 323 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 12.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +51.16% in the last 52 weeks. The beta is 0.76, so TARS's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +51.16% |
| 50-Day Moving Average | 62.17 |
| 200-Day Moving Average | 50.32 |
| Relative Strength Index (RSI) | 64.12 |
| Average Volume (20 Days) | 535,612 |
Short Selling Information
The latest short interest is 7.03 million, so 16.64% of the outstanding shares have been sold short.
| Short Interest | 7.03M |
| Short Previous Month | 7.24M |
| Short % of Shares Out | 16.64% |
| Short % of Float | 23.12% |
| Short Ratio (days to cover) | 10.32 |
Income Statement
In the last 12 months, TARS had revenue of $366.10 million and -$81.16 million in losses. Loss per share was -$1.99.
| Revenue | 366.10M |
| Gross Profit | 324.54M |
| Operating Income | -87.41M |
| Pretax Income | -81.16M |
| Net Income | -81.16M |
| EBITDA | -85.61M |
| EBIT | -87.41M |
| Loss Per Share | -$1.99 |
Full Income StatementBalance Sheet
The company has $401.84 million in cash and $72.28 million in debt, giving a net cash position of $329.56 million or $7.81 per share.
| Cash & Cash Equivalents | 401.84M |
| Total Debt | 72.28M |
| Net Cash | 329.56M |
| Net Cash Per Share | $7.81 |
| Equity (Book Value) | 335.08M |
| Book Value Per Share | 7.89 |
| Working Capital | 384.65M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$53.96 million and capital expenditures -$3.57 million, giving a free cash flow of -$57.54 million.
| Operating Cash Flow | -53.96M |
| Capital Expenditures | -3.57M |
| Free Cash Flow | -57.54M |
| FCF Per Share | -$1.36 |
Full Cash Flow StatementMargins
Gross margin is 88.65%, with operating and profit margins of -23.88% and -22.17%.
| Gross Margin | 88.65% |
| Operating Margin | -23.88% |
| Pretax Margin | -22.17% |
| Profit Margin | -22.17% |
| EBITDA Margin | -23.38% |
| EBIT Margin | -23.88% |
| FCF Margin | n/a |
Dividends & Yields
TARS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.73% |
| Shareholder Yield | -12.73% |
| Earnings Yield | -2.69% |
| FCF Yield | -1.91% |
Analyst Forecast
The average price target for TARS is $69.43, which is -2.90% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $69.43 |
| Price Target Difference | -2.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 42.07% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
